Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (151-160 of 223) with videos related to

Pageof 23
Sort By:
Annals of Neurology|April 26, 2017
Prognostic indicators in pediatric clinically isolated syndromePietro Iaffaldano, Marta Simone, Giuseppe Lucisano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Plos One|June 6, 2015
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSKaren Ann Ribbons, Patrick McElduff, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Pageof 23

Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Annals of Neurology|April 26, 2017
Prognostic indicators in pediatric clinically isolated syndromePietro Iaffaldano, Marta Simone, Giuseppe Lucisano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Plos One|June 6, 2015
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSKaren Ann Ribbons, Patrick McElduff, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Pageof 23